Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

Blood

Volumn 95, Issue 12, 2000, Pages 4008-4010

  Desikan, Raman ^b   Barlogie, Bart ^a   Sawyer, Jeffrey ^b   Ayers, Dan ^b   Tricot, Guido ^b   Badros, Ashraf ^b   Zangari, Maurizio ^b   Munshi, Nikhil C ^b   Anaissie, Elias ^b   Spoon, Dan ^b   Siegel, David ^b   Jagannath, Sundar ^b   Vesole, David ^b   Epstein, Joshua ^b   Shaughnessy, John ^b   Fassas, Athanasios ^b   Lim, Seah ^b   Roberson, Paula ^b   Crowley, John ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; MELPHALAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME 13; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL;

EID: 18544409610     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.4008.012k03_4008_4010     Document Type: Article

References (25)

1. McElwain T, Powles R. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet. 1983;2:822-824.
2. Barlogie B, Alexanian R, Dicke K, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869-872.
3. Harousseau J, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood. 1995;85:3077-3085.
4. Attal M, Harousseau J, Stoppa A, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
5. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
6. Sawyer J, Waldron J, Jagannath S, Barlogie B. Cytogenetics findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995; 82:41-49.
7. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;7:484-489.
8. Desikan K, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral blood stem cell infusion mobilized with G-CSF with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998;16:1547-1553.
9. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
10. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-1054.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
13. Cox DR. Regression models and life-tables [with discussion]. J Royal Stat Soc, Series B. 1972;34: 187-220.
14. Crowley J, Hu M. Covariance analysis of heart transplant survival data. J Am Stat Assoc. 1977; 72:27-36.
15. Anderson JR, Cain CC, Gelber RD, Gelman RS. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep. 1985;69(1):1139-1146.
16. Attal M, Harousseau L, Facon T, et al. Single versus double transplant in myeloma: a randomized trial of the "Inter Groupe Francais Du Myelome" (IFM). Blood. 1999;94:714a.
17. Bjorkstrand BT, Svensson H, Goldschmidt H, et al. 5489 Autotransplants in multiple myeloma - a registry study from the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1999;94:714a.
18. Tosi P, Cavo M, Zamagni E, Ronconi S, Benni M, Tura S. A multicentric randomized clinical trial comparing single vs double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: results of an interim analysis. Blood. 1999;94:715a.
19. Finke J, Bertz H, Veelken H, et al. In vivo T cell depletion with ATG reduces GVHD in unrelated donor stem cell transplantation. Blood. 1999;94: 713a.
20. Barlogie B, Desikan R, Munshi N, et al. Single course D.T. PACE anti-angiochemotherapy affects CR in plasma cell leukemia and fulminant multiple myeloma (MM). Blood. 1998;92:4180a.
21. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
22. Desikan R, Munshi N, Zangari M. et al. DCEP consolidation chemotherapy (CC) after 2 cycles of melphalan-based high dose therapy (HDT) -high incidence of CR and superior outcome in comparison with matched historical controls. Blood. 1999;94:316a.
23. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
24. Tricot G, Vesole D, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.
25. Barlogie B, Desikan R, Munshi N, et al. Durable CR in multiple myeloma (MM) in the absence of chromosome 13 deletion (Δ13) and with tandem melphalan-based high dose therapy (HDT) - the Arkansas Experience with 1000 consecutive patients. Blood. 1999;94:714a.